对化疗和免疫疗法的表观遗传学程序性耐药性。

2区医学 Q1 Medicine Advances in Cancer Research Pub Date : 2023-01-01 Epub Date: 2023-01-27 DOI:10.1016/bs.acr.2022.12.001

Reddick R Walker, Zainab Rentia, Katherine B Chiappinelli

{"title":"对化疗和免疫疗法的表观遗传学程序性耐药性。","authors":"Reddick R Walker, Zainab Rentia, Katherine B Chiappinelli","doi":"10.1016/bs.acr.2022.12.001","DOIUrl":null,"url":null,"abstract":"Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"158 ","pages":"41-71"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184181/pdf/nihms-1897571.pdf","citationCount":"0","resultStr":"{\"title\":\"Epigenetically programmed resistance to chemo- and immuno-therapies.\",\"authors\":\"Reddick R Walker, Zainab Rentia, Katherine B Chiappinelli\",\"doi\":\"10.1016/bs.acr.2022.12.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.\",\"PeriodicalId\":50875,\"journal\":{\"name\":\"Advances in Cancer Research\",\"volume\":\"158 \",\"pages\":\"41-71\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184181/pdf/nihms-1897571.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Cancer Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/bs.acr.2022.12.001\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/27 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/bs.acr.2022.12.001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

对癌症治疗的耐药性仍然是开发癌症治疗方法的主要障碍。尽管有希望的联合化疗和新型免疫疗法改善了患者的预后，但对这些治疗的耐药性仍知之甚少。对表观基因组失调的新见解显示了它如何促进肿瘤生长和对治疗的耐药性。通过改变基因表达的控制，肿瘤细胞可以逃避免疫细胞的识别，忽略凋亡线索，并逆转化疗诱导的DNA损伤。在本章中，我们总结了癌症进展和治疗过程中表观遗传学重塑的数据，这些数据使癌症细胞存活，并描述了这些表观遗传学变化如何在临床上被靶向以克服耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Epigenetically programmed resistance to chemo- and immuno-therapies.

Resistance to cancer treatments remains a major barrier in developing cancer cures. While promising combination chemotherapy treatments and novel immunotherapies have improved patient outcomes, resistance to these treatments remains poorly understood. New insights into the dysregulation of the epigenome show how it promotes tumor growth and resistance to therapy. By altering control of gene expression, tumor cells can evade immune cell recognition, ignore apoptotic cues, and reverse DNA damage induced by chemotherapies. In this chapter, we summarize the data on epigenetic remodeling during cancer progression and treatment that enable cancer cell survival and describe how these epigenetic changes are being targeted clinically to overcome resistance.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Advances in Cancer Research 医学-肿瘤学

CiteScore

10.00

自引率

0.00%

发文量

期刊介绍： Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. Advances in Cancer Research (ACR) has covered a remarkable period of discovery that encompasses the beginning of the revolution in biology. The first ACR volume came out in the year that Watson and Crick reported on the central dogma of biology, the DNA double helix. In the first 100 volumes are found many contributions by some of those who helped shape the revolution and who made many of the remarkable discoveries in cancer research that have developed from it.